Nine years after selling Medivation to Pfizer for $14 billion, David Hung, M.D., is going toe to toe with the New York ...

This next-generation ROS1 tyrosine kinase inhibitor previously received breakthrough therapy and orphan drug designations for ...

Nuvation Bio (NUVB) wins U.S. FDA approval for its oral antitumor agent Ibtrozi as a treatment for certain patients with non-small cell lung cancer. Read more here.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

"The FDA approval of IBTROZI marks a major milestone in the evolution of targeted therapy for advanced ROS1-positive NSCLC," said David Hung, M.D., Founder, President and Chief Executive Officer of ...

Study reveals the advantages and pitfalls of adding a TKI to a monoclonal antibody after chemoradiation for non-small cell ...